Table 1.
Baseline Sociodemographic and Clinical Characteristics of Cohort Members Assessed at Follow-up (n = 243) and Those not Assessed (n = 267)
| Assessed | Not Assessed | X 2 or t(df) | P | |
|---|---|---|---|---|
| Gender, female, n (%) | 106 (43.6) | 100 (37.5) | 2.010(1) | 0.156 |
| Age, y | 27.5 (9.83) | 31.8 (12.6) | 4.197(508) | <.001 |
| Socioeconomic status score (1–5) | 3.07 (0.72) | 3.16 (0.67) | 1.475(508) | .141 |
| Married/cohabiting at illness onset, n (%) | 73 (30.0) | 94 (35.2) | 1.541(1) | .214 |
| Education, years | 11.2 (3.37) | 10.6 (3.43) | 1.865(508) | .063 |
| Premorbid adjustment total score | 5.32 (4.23) | 5.61 (3.78) | 0.837(508) | .403 |
| DUP, months | 15.3 (35.2) | 20.2 (44.5) | 1.388(498.8) | .166 |
| Drug use before admission, n (%) | 81 (33.3) | 100 (37.5) | 0.943(1) | .331 |
| Type of onset (1 = acute, 4 = chronic) | 2.59 (1.23) | 2.72 (1.19) | 1.21(508) | .226 |
| Compulsory admission, n (%) | 76 (31.3) | 87 (32.6) | 0.100(1) | .752 |
| Antipsychotic drug-naïve status, n (%) | 194 (79.8) | 199 (74.5) | 2.024(1) | .155 |
| Diagnosis, n (%) | ||||
| Schizophrenia | 72 (29.6) | 89 (33.3) | 2.262(7) | .944 |
| Schizophreniform disorder | 40 (16.5) | 39 (14.6) | ||
| Brief psychotic disorder | 41 (16.9) | 40 (15.0) | ||
| Delusional disorder | 16 (6.6) | 23 (8.6) | ||
| Schizoaffective disorder | 13 (5.3) | 12 (4.5) | ||
| Mania/bipolar disorder | 20 (8.2) | 23 (8.6) | ||
| Major depressive disorder | 29 (11.9) | 30 (11.2) | ||
| Psychotic disorder NOS | 12 (4.9) | 11 (4.1) | ||
| Length of index admission, weeks | 3.00 (1.78) | 3.13 (2.02) | 0.771(508) | .441 |
| SAPS, global ratings total score | 9.57 (4.09) | 8.97 (4.07) | 1.662(508) | .097 |
| SANS, global ratings total score | 4.96 (5.23) | 5.49 (5.35) | 1.115(508) | .265 |
| CGI, Efficacy Index | 1.56 (0.77) | 1.66 (0.91) | 1.434(505.7) | .152 |
Note: DUP, duration of untreated psychosis; NOS, not otherwise specified; SAPS, scale for the assessment of positive symptoms; SANS, scale for the assessment of negative symptoms; CGI, clinical global impression.